Brief: Astellas Pharma Inc - Sales In U.S. Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Treatment Of Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration In Q1 Of Fy2025 Was ¥15.9 Billion/ $110 Million
10/07/2025 24:32
July 10 (Reuters) - Astellas Pharma Inc 4503.T: ASTELLAS PHARMA INC: SALES IN U.S. OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR TREATMENT OF GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION IN Q1 OF FY2025 WAS ¥15.9 BILLION/ $110 MILLION Source text: ID:nTSsi7cc36 Further company coverage: 4503.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn